Frequently Asked Questions about Arcutis Biotherapeutics, Inc. (ARQT)

Name: Arcutis Biotherapeutics, Inc. (ARQT) Institutional Financial Dataset
Creator: Olyth
License: https://olyth.xyz

Question 1

What does Arcutis Biotherapeutics, Inc. (ARQT) do?

Accepted Answer

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atop...

Question 2

Is Arcutis Biotherapeutics, Inc. (ARQT) a good stock to buy?

Accepted Answer

Olyth's institutional analysis of ARQT reveals an Altman Z-Score of 5.15 and a Piotroski F-Score of 4/9. These metrics, combined with its 5-year revenue trend ($0.38B most recent), help investors decide if ARQT fits their risk profile.

Question 3

What is the current P/E ratio for ARQT?

Accepted Answer

As of the latest trading session, Arcutis Biotherapeutics, Inc. (ARQT) has a trailing P/E ratio of -184.90.

Question 4

Who is the CEO of Arcutis Biotherapeutics, Inc.?

Accepted Answer

The current Chief Executive Officer of Arcutis Biotherapeutics, Inc. is Todd Franklin Watanabe.

Question 5

What was ARQT's revenue for the last 5 years?

Accepted Answer

According to its latest income statements, Arcutis Biotherapeutics, Inc. reported annual revenues of $0.38B (2025), $0.20B (2024), $0.06B (2023), $0.00B (2022), $0.00B (2021) respectively.

Question 6

Does ARQT pay a dividend?

Accepted Answer

Arcutis Biotherapeutics, Inc. does not currently pay a dividend to its shareholders.

Question 7

How much debt and cash flow does ARQT have?

Accepted Answer

In its latest reporting period, Arcutis Biotherapeutics, Inc. generated $-0.01B in Free Cash Flow against a total debt load of $0.01B.

Question 8

What is the Price-to-Book (P/B) ratio of Arcutis Biotherapeutics, Inc.?

Accepted Answer

The Price-to-Book (P/B) ratio for Arcutis Biotherapeutics, Inc. (ARQT) is currently 15.75.

Question 9

What is the Price-to-Sales (P/S) ratio of ARQT?

Accepted Answer

Based on trailing twelve-month data, Arcutis Biotherapeutics, Inc. (ARQT) trades at a Price-to-Sales (P/S) ratio of 7.67.

Question 10

What is Arcutis Biotherapeutics, Inc.'s Return on Equity (ROE)?

Accepted Answer

Arcutis Biotherapeutics, Inc. (ARQT) has a Return on Equity (ROE) of -10.26%, representing its profitability relative to shareholder equity.

ARQT

Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales

Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales

Phocas Financial Corp. Sells 41,808 Shares of Arcutis Biotherapeutics, Inc. $ARQT

Arcutis Management to Present at the 25th Annual Needham Virtual Healthcare Conference

Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual Meeting

Arcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters at the 2026 American Academy of Dermatology Annual Meeting

Ally Bridge Group NY LLC Invests $4.40 Million in Arcutis Biotherapeutics, Inc. $ARQT